England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

Second major approval for Blenrep combinations, with more expected in 2025 This is the second major regulatory approval for Blenrep combinations for the treatment of relapsed or refractory ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory ...

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma. The London-based ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.